Skip to main content
SpringerLink
Log in

Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure

Current Status and Future Directions

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Heart failure is a serious worldwide health problem of major proportions. For many physicians, digitalis (an inotropic agent of limited proportions) and diuretics have proven the standard of treatment for heart failure. Vasodilators have also gained acceptance in recent years.

Nevertheless, many patients remain symptomatic and therefore attention has been given to the development of pharmacological agents with mechanisms of action targeted to cardiac and vascular smooth muscle. The newer generation of inotropic agents have clearly been shown to improve the pumping function of the failing heart in patients who remain symptomatic despite digitalis, diuretics and vasodilators, while myocardial oxygen consumption is not enhanced. Several uncontrolled trials with the phosphodiesterase inhibitors enoximone, milrinone and piroximone have concluded that these agents improve exercise capacity and thereby hold promise to enchance quality of life. Large scale controlled trials currently in progress will determine the ultimate efficacy, as well as safety, of these agents. Results to date with several orally active β-adrenoceptor agonists suggest that their efficacy may be limited by the induction of ventricular arrhythmias.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alousi A, Farah A, Lesher G, Opalka C. Cardiotonic activity of amrinone — WIN 40680 (5-amino-3,4-bipyridin-6(1H)-one). Circulation Research 45: 666–677, 1979

    Article  PubMed  CAS  Google Scholar 

  • Amin DK, Shah PK, Hülse S, Shellock F. Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL 17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure. American Heart Journal 109: 1006–1012, 1985

    Article  PubMed  CAS  Google Scholar 

  • Amin DK, Shah PK, Hulse S, Shellock FG, Swan HJC. Myocardial metabolic and hemodynamic effects of intravenous MDL 17,043, a new cardiotonic drug, in patients with chronic, severe heart failure. American Heart Journal 108: 1285–1292, 1984

    Article  PubMed  CAS  Google Scholar 

  • Amin DK, Shah PK, Shellock FG, Hulse S, Brandon G, et al. Comparative hemodynamic effects of intravenous dobutamine and MDL 17,043, a new cardioactive drug, in severe congestive heart failure. American Heart Journal 109: 91–98, 1985

    Article  PubMed  CAS  Google Scholar 

  • Applefeld MM, Newman KA, Grove WR, Sutton EJ, Roffman DS, et al. Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure. American Journal of Cardiology 51: 455–458, 1983

    Article  PubMed  CAS  Google Scholar 

  • Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, et al. Evaluation of a new bipyridine inotropic agent — milrinone — in patients with congestive heart failure. New England Journal of Medicine 309: 748–756, 1983

    Article  PubMed  CAS  Google Scholar 

  • Baim DS, Rothman MT, Harrison DC. Improved catheter for regional coronary sinus flow and metabolic studies. American Journal of Cardiology 46: 997–1000, 1980

    Article  PubMed  CAS  Google Scholar 

  • Bendersky R, Chatterjee K, Parmley WW, Brundage BH, Ports TA. Dobutamine in chronic ischemic heart failure: alterations in left ventricular function and coronary hemodynamics. American Journal of Cardiology 48: 554–558, 1981

    Article  PubMed  CAS  Google Scholar 

  • Benotti J, Grossman W, Braunwald E, Carabello BA. Effects of amrinone on hemodynamics and myocardial metabolism in patients with congestive heart failure from ischemic heart disease. Circulation 62: 28–34, 1980

    Article  PubMed  CAS  Google Scholar 

  • Benotti J, Grossman W, Braunwald E, Davolos DD, Alousi AA. Hemodynamic assessment of amrinone: a new vasoactive agent. New England Journal of Medicine 299: 1373–1377, 1978

    Article  PubMed  CAS  Google Scholar 

  • Bristow MR, Ginsburg R, Minobe W, Cubiceiotti RS, Sageman WS, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. New England Journal of Medicine 307: 205–211, 1982

    Article  PubMed  CAS  Google Scholar 

  • Califf RM, Bounous P, Harrell FE, McCants B, Lee KL, et al. The prognosis in the presence of coronary artery disease. In Braunwald et al. (Eds) Congestive heart failure: current research and clinical applications, pp. 31–40, Grune & Stratton, New York, 1982

    Google Scholar 

  • Cohn JN. Clinical definitions and studies. In Braunwald et al. (Eds) Congestive heart failure: current research and clinical applications, pp. 11–13, Grune & Stratton, New York, 1982

    Google Scholar 

  • Colucci WS, Alexander RW, Williams GH, Rude RE, Holman BL, et al. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. New England Journal of Medicine 305: 185–191, 1981

    Article  PubMed  CAS  Google Scholar 

  • DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. Journal of the American College of Cardiology 4: 855–866, 1984

    Article  PubMed  CAS  Google Scholar 

  • Endoh M, Yamashita S, Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. Journal of Pharmacology and Experimental Therapeutics 221: 775–783, 1982

    PubMed  CAS  Google Scholar 

  • Fabiato A. Effects of cyclic AMP and phosphodiesterase inhibitors on the contractile activation and the Ca2+ transient detected with aequorin in skinned cardiac cells from rat and rabbit ventricles. Journal of General Physiology 78: 15a–16a, 1981

    Article  Google Scholar 

  • Gibson TC, White KL, Klainer LM. Prevalence of congestive heart failure in two rural communities. Journal of Chronic Diseases 19: 141–152, 1966

    Article  PubMed  CAS  Google Scholar 

  • Harrison TR, Reeves TJ. Principles and problems of ischemic heart disease, p. 24, Year Book Medical Publishers, Chicago, 1968

    Google Scholar 

  • Jeliffe RW, Buell J, Kalaba R. Reduction of digitalis toxicity by computer-assisted glycoside dosage regimens. Annals of Internal Medicine 77: 891–897, 1972

    Google Scholar 

  • Kannel WB, Savage D, Castelli WP. Cardiac failure in the Framingham study: twenty year follow up. In Braunwald et al. (Eds) Congestive heart failure: current research and clinical applications, pp. 15–30, Grune & Stratton, New York, 1982

    Google Scholar 

  • Katz AM, Smith VE. Relaxation abnormalities, part I: mechanisms. Hospital Practice, pp. 69–83, Jan, 1984

    Google Scholar 

  • Kereiakas D, Chatterjee K, Parmley WW, Atherton B, Curran D, et al. Intravenous and oral MDL 17,043 (a new inotropic-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. Journal of the American College of Cardiology 4: 884–889, 1984

    Article  Google Scholar 

  • Lambert H, Meyer J, Erbel R. Long term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 69: 298, 1984

    Article  Google Scholar 

  • LeJemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, et al. Amrinone: a new nonglycosidic, nonadrenergic cardiotonic agent in the treatment of intractable myocardial failure in man. Circulation 59: 1098–1104, 1979

    Article  PubMed  CAS  Google Scholar 

  • LeJemtel TH, Maskin CS, Mancini D, Sinoway L, Feld H, et al. Systemic and regional hemodynamic effects of Captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation 72: 364–369, 1985

    Article  PubMed  CAS  Google Scholar 

  • Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, et al. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. Circulation 69: 113–119, 1984

    Article  PubMed  CAS  Google Scholar 

  • Likoff MJ, Weber KT, Andrews V, Janicki JS, St John Sutton M, et al. Amrinone in the treatment of chronic cardiac failure. Journal of the American College of Cardiology 3: 1282–1290, 1984

    Article  PubMed  CAS  Google Scholar 

  • Likoff MJ, Weber KT, Andrews V, Janicki JS, Wilson H, et al. Milrinone in the treatment of chronic cardiac failure: a controlled trial. American Heart Journal 110: 1035–1042, 1985

    Article  PubMed  CAS  Google Scholar 

  • Martin JL, Likoff MJ, Janicki JS, Laskey WK, Hirschfeld JW, et al. Myocardial energetics and clinical response to the cardiotonic agent MDL 17,043 in advanced heart failure. Journal of the American College of Cardiology 4: 875–883, 1984

    Article  PubMed  CAS  Google Scholar 

  • Maskin CS, Forman R, Sonnenblick EH, Frishman WH, Le-Jemtel TH. Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure. American Journal of Cardiology 51: 177–182, 1983a

    Article  PubMed  CAS  Google Scholar 

  • Maskin CS, Kugler J, Sonnenblick EH, LeJemtel TH. Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise. American Journal of Cardiology 52: 1028–1032, 1983a

    Article  PubMed  CAS  Google Scholar 

  • Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, LeJemtel TH. Sustained hemodynamic and clinical effects of a new cardiotonic agent WIN 47203 in patients with severe congestive heart failure. Circulation 67: 1065–1070, 1983b

    Article  PubMed  CAS  Google Scholar 

  • Maskin CS, Siskind SJ, LeJemtel TH. High prevalence of non-sustained ventricular tachycardia in severe congestive heart failure. American Heart Journal 107: 896–901, 1984

    Article  PubMed  CAS  Google Scholar 

  • Massie B, Ports T, Chatterjee K, Parmley W, Ostland J, et al. Long term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278, 1981

    Article  PubMed  CAS  Google Scholar 

  • Monrad ES, Baim DS, Smith HS, Lanone AS, Braunwald E, et al. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 71: 972–979, 1985

    Article  PubMed  CAS  Google Scholar 

  • Petein M, Levine TB, Cohn JN. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19,205), in patients with chronic heart failure. Journal of the American College of Cardiology 4: 364–371, 1984

    Article  PubMed  CAS  Google Scholar 

  • Roubin GS, Choong CYP, Devenish-Meares S, Sadick NN, Fletcher PJ, et al. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol. Circulation 69: 955, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rubin SA, Tabak L. MDL 17,043: Short- and long-term cardiopulmonary and clinical effects in patients with heart failure. Journal of the American College of Cardiology 5: 1422–1427, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rude RE, Turi Z, Brown EJ, Lorell BH, Colucci WS, et al. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure. Circulation 64: 139–145, 1981

    Article  PubMed  CAS  Google Scholar 

  • Scholz H. Inotropic drugs and their mechanism of action. Journal of the American College of Cardiology 4: 389–397, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Scholz H. Inotropic drugs in the treatment of heart failure. Hospital Practice, pp. 57–71, May 1984b

    Google Scholar 

  • Shah PS, Amin DK, Hulse S, Shellock F, Swan HJC. Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL 17,043): poor long-term results despite early hemodynamic and clinical improvement. Circulation 71: 326–331, 1985

    Article  PubMed  CAS  Google Scholar 

  • Shah S, Weber KT, Maskin CS. Sustained clinical and hemodynamic benefits of intermittent amrinone infusion in patients with severe chronic cardiac failure. Circulation 72: III–403, 1985

    Google Scholar 

  • Simonton CA, Chatterjee K, Cody RJ, Kubo SH, Leonard D, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. Journal of the American College of Cardiology 6: 453–459, 1985

    Article  PubMed  CAS  Google Scholar 

  • Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, et al. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. Journal of the American College of Cardiology 2: 327–331, 1983

    Article  PubMed  CAS  Google Scholar 

  • Siskind SJ, Sonnenblick EH, Forman R, Scheuer J, LeJemtel TH. Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure. Circulation 64: 966–971, 1981

    Article  PubMed  CAS  Google Scholar 

  • Smith MR. Epidemiology of congestive heart failure. American Journal of Cardiology 55: 3A–8A, 1985

    Article  PubMed  CAS  Google Scholar 

  • Strain J, Grose R, Maskin CS, LeJemtel TH. Effects of a new cardiotonic agent, MDL 17,043, on myocardial contractility and left ventricular performance in congestive heart failure. American Heart Journal 110: 91–96, 1985

    Article  PubMed  CAS  Google Scholar 

  • Unverferth DV, Magorien RD, Altschuld R, Kolibash AJ, Lewis RP. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine. American Heart Journal 106: 29–34, 1983

    Article  PubMed  CAS  Google Scholar 

  • Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WB. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation 67: 823–828, 1983

    Article  PubMed  CAS  Google Scholar 

  • Uretsky BF, Generalovich T, Verbalis JG, Valdes AM, Reddy PS. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. Journal of the American College of Cardiology 5: 1414–1421, 1985

    Article  PubMed  CAS  Google Scholar 

  • Viquerat CE, Kereiakes D, Morris L, Daly PA, Wexman M, et al. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17,043, a new inotropic vasodilator agent in patients with severe heart failure. Journal of the American College of Cardiology 5: 326–332, 1985

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Andrews V, Janicki JS, Likoff MJ, Reichek N. Pirbuterol, an oral beta-adrenergic receptor agonist in the treatment of chronic cardiac failure. Circulation 66: 1262–1267, 1982

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Andrews V, Janicki JS, Wilson JR, Fishman AP. Amrinone and exercise performance in patients with chronic heart failure. American Journal of Cardiology 48: 164–169, 1981

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS, Jain MC. Enoximone (MDL 17,043) for stable chronic cardiac failure secondary to ischemic or idiopathic cardiomyopathy. American Journal of Cardiology 58: 589–595, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS, Jain MC. Enoximone (MDL 17,043), a phophodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure. Journal of Heart Transplantation 5: 105–112, 1986b

    PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS, Jain MC. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. American Heart Journal, in press, 1987

    Google Scholar 

  • Weber KT, Janicki JS, Maskin CS. Pathophysiology of cardiac failure. American Journal of Cardiology 56: 3B–7B, 1985

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS, Reeves RC, Hefner LL. Factors influencing left ventricular shortening in isolated canine heart. American Journal of Physiology 230: 419–426, 1976

    PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. American Journal of Cardiology 55: 22A–31A, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS. Lactate production during maximal and submaximal exercise in patients with chronic heart failure. Journal of the American College of Cardiology 6: 717–724, 1985b

    Article  PubMed  CAS  Google Scholar 

  • Weber KT, Janicki JS. The metabolic demand and O2 supply of the heart: physiological and clinical considerations. American Journal of Cardiology 44: 722–729, 1979

    Article  PubMed  CAS  Google Scholar 

  • Weber KT. New hope for the failing heart. American Journal of Medicine 72: 665–671, 1982

    Article  PubMed  CAS  Google Scholar 

  • Weishaar RE, Cain MH, Bristol JA. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. Journal of Medicinal Chemistry 28: 537–545, 1985

    Article  PubMed  CAS  Google Scholar 

  • White HD, Ribeiro JP, Hartley LH, Colucci WS. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. American Journal of Cardiology 56: 93–98, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wilson JR, Martin JL, Ferraro N, Weber KT. Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure. Circulation 68: 425–431, 1983a

    Article  PubMed  CAS  Google Scholar 

  • Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine. American Journal of Cardiology 53: 1308–1314, 1984

    Article  PubMed  CAS  Google Scholar 

  • Wilson JR, Schwartz S, St John Sutton M, Ferraro N, Horowitz LN, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. Journal of the American College of Cardiology 2: 403–410, 1983b

    Article  PubMed  CAS  Google Scholar 

  • Withering W. An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases, Boehringer Mannheim GmbH, Mannheim, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Michael Reese Hospital, University of Chicago, Chicago, USA

    Karl T. Weber, Santosh K. Gill, Joseph S. Janicki, Carol S. Maskin & Mukesh C. Jain

Authors
  1. Karl T. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Santosh K. Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph S. Janicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carol S. Maskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mukesh C. Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weber, K.T., Gill, S.K., Janicki, J.S. et al. Newer Positive Inotropic Agents in the Treatment of Chronic Cardiac Failure. Drugs 33, 503–519 (1987). https://doi.org/10.2165/00003495-198733050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198733050-00005

Keywords

Search

Navigation